Cargando…
Molecular Mechanism of Sulphonylurea Block of K(ATP) Channels Carrying Mutations That Impair ATP Inhibition and Cause Neonatal Diabetes
Sulphonylurea drugs are the therapy of choice for treating neonatal diabetes (ND) caused by mutations in the ATP-sensitive K(+) channel (K(ATP) channel). We investigated the interactions between MgATP, MgADP, and the sulphonylurea gliclazide with K(ATP) channels expressed in Xenopus oocytes. In the...
Autores principales: | Proks, Peter, de Wet, Heidi, Ashcroft, Frances M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806600/ https://www.ncbi.nlm.nih.gov/pubmed/23835339 http://dx.doi.org/10.2337/db13-0531 |
Ejemplares similares
-
Binding of sulphonylureas to plasma proteins – A K(ATP) channel perspective
por: Proks, Peter, et al.
Publicado: (2018) -
Molecular action of sulphonylureas on K(ATP) channels: a real partnership between drugs and nucleotides
por: de Wet, Heidi, et al.
Publicado: (2015) -
Activation of the K(ATP) channel by Mg-nucleotide interaction with SUR1
por: Proks, Peter, et al.
Publicado: (2010) -
How ATP Inhibits the Open K(ATP) Channel
por: Craig, Tim J., et al.
Publicado: (2008) -
Molecular Analysis of ATP-sensitive K Channel Gating and Implications for Channel Inhibition by ATP
por: Trapp, Stefan, et al.
Publicado: (1998)